Closely held Ennaid Therapeutics is advancing development of ENU200 as a therapeutic to treat the up to 80% of asymptomatic, mild-to-moderate cases of COVID-19 viral infections. ENU200 is a repurposed, patent-pending...

Closely held Kleo Pharmaceuticals entered into a research collaboration with South Korea-based Green Cross LabCell, a pioneer in the next generation of allogeneic, or “off-the-shelf” natural killer cell...